dmhca

**DMHCA** is a synthetic small molecule and experimental pharmaceutical described as a selective agonist of the **liver X receptor (LXR)**, specifically the LXRα and LXRβ subtypes. Unlike other LXR agonists, DMHCA activates the cholesterol efflux arm of the LXR pathway without stimulating triglyceride synthesis, thus avoiding the undesirable side effects of hypertriglyceridemia and hepatic steatosis. DMHCA also inhibits **Δ24-dehydrocholesterol reductase (DHCR24)**, decreasing cholesterol biosynthesis and leading to accumulation of desmosterol, a potent endogenous LXR agonist. DMHCA is studied in preclinical models for conditions associated with cholesterol dysregulation, such as diabetic retinopathy, bone marrow dysfunctions in diabetes, atherosclerosis, and age-related macular degeneration. It restores cholesterol homeostasis in affected tissues, improves membrane fluidity in hematopoietic progenitor and vascular reparative cells, reduces inflammation, and corrects diabetes-induced retinal and bone marrow pathology[1][2][3][4][5][6].

Other names

DMHCAN,N-dimethyl-3β-hydroxycholenamideN,N-dimethyl-3beta-hydroxycholenamideDimethyl-HCA